These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 22679718)
1. [Effects of naoxintong capsule on the inflammation and prognosis in borderline lesion coronary heart disease patients]. Li SR; Wang TH; Zhang BJ Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 May; 32(5):607-11. PubMed ID: 22679718 [TBL] [Abstract][Full Text] [Related]
2. [Efficacy assessment of treating patients with coronary heart disease angina of phlegm and stasis mutual obstruction syndrome by Danlou tablet]. Wang SH; Wang J; Li J Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Aug; 32(8):1051-5. PubMed ID: 23173251 [TBL] [Abstract][Full Text] [Related]
3. [Effects of ApoE gene polymorphism on anti-inflammatory action of xuezhikang capsule]. Jiang WM; Fang ZY; Zhu CL; Tang SH Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jan; 33(1):35-9. PubMed ID: 23596783 [TBL] [Abstract][Full Text] [Related]
4. Comparision of high sensitivity C-reactive protein and matrix metalloproteinase 9 in patients with unstable angina between with and without significant coronary artery plaques. Wang LX; Lü SZ; Zhang WJ; Song XT; Chen H; Zhang LJ Chin Med J (Engl); 2011 Jun; 124(11):1657-61. PubMed ID: 21740772 [TBL] [Abstract][Full Text] [Related]
5. [Intravascular ultrasound study of coronary remodeling and determination of matrix metalloproteinase and hypersensitive C-reactive protein]. Hui B; Dang Q; Wang XF; Jin Z; Xia DS; Gao L; Cai L; Zhang J; Xu F; Wang PX Zhonghua Xin Xue Guan Bing Za Zhi; 2005 May; 33(5):428-32. PubMed ID: 15932701 [TBL] [Abstract][Full Text] [Related]
6. [Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention]. Jiang FY; Sun LP; Yang J Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Dec; 31(12):1607-10. PubMed ID: 22384544 [TBL] [Abstract][Full Text] [Related]
7. [Associations between the plasma inflammatory markers and plaque morphologies of coronary artery lesions]. Wang X; Hu DY; Yang SW; Zhang J; Tan C; Zhang SY Zhonghua Nei Ke Za Zhi; 2008 Jan; 47(1):27-30. PubMed ID: 18346322 [TBL] [Abstract][Full Text] [Related]
8. Plasma neutrophil gelatinase-associated lipocalin levels are associated with the presence and severity of coronary heart disease. Li C; Zhang Z; Peng Y; Gao H; Wang Y; Zhao J; Pan C PLoS One; 2019; 14(8):e0220841. PubMed ID: 31387110 [TBL] [Abstract][Full Text] [Related]
9. [Effects of Xuezhikang on serum levels of high sensitive-C reactive protein, matrix metalloproteinase-9 and lipoprotein in patients with acute coronary syndrome]. Huang J; Wang MH; Peng XP; Wei C; Lu J Zhongguo Zhong Xi Yi Jie He Za Zhi; 2006 Mar; 26(3):221-3. PubMed ID: 16613266 [TBL] [Abstract][Full Text] [Related]
10. Serial changes in plasma levels of cytokines in patients with coronary artery disease. Heinisch RH; Zanetti CR; Comin F; Fernandes JL; Ramires JA; Serrano CV Vasc Health Risk Manag; 2005; 1(3):245-50. PubMed ID: 17319110 [TBL] [Abstract][Full Text] [Related]
11. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. Schieffer B; Bünte C; Witte J; Hoeper K; Böger RH; Schwedhelm E; Drexler H J Am Coll Cardiol; 2004 Jul; 44(2):362-8. PubMed ID: 15261932 [TBL] [Abstract][Full Text] [Related]
12. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Zeng B; Prasan A; Fung KC; Solanki V; Bruce D; Freedman SB; Brieger D Intern Med J; 2005 Jun; 35(6):331-5. PubMed ID: 15892761 [TBL] [Abstract][Full Text] [Related]
13. Inflammatory markers, angiographic severity of coronary artery disease, and patient outcome. Sukhija R; Fahdi I; Garza L; Fink L; Scott M; Aude W; Pacheco R; Bursac Z; Grant A; Mehta JL Am J Cardiol; 2007 Apr; 99(7):879-84. PubMed ID: 17398176 [TBL] [Abstract][Full Text] [Related]
14. Involvement of inflammation in acute coronary syndromes assessed by levels of high-sensitivity C-reactive protein, matrix metalloproteinase-9 and soluble vascular-cell adhesion molecule-1. Nomoto K; Oguchi S; Watanabe I; Kushiro T; Kanmatsuse K J Cardiol; 2003 Nov; 42(5):201-6. PubMed ID: 14658408 [TBL] [Abstract][Full Text] [Related]
15. Correlation Analysis of Acute Coronary Syndrome with Serum IL-18, MMP-9, hs-CRP, and Plasma FIB. Yang Y; Li G; Zhang R Biomed Res Int; 2022; 2022():5984184. PubMed ID: 35028315 [TBL] [Abstract][Full Text] [Related]
16. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Brown DL; Desai KK; Vakili BA; Nouneh C; Lee HM; Golub LM Arterioscler Thromb Vasc Biol; 2004 Apr; 24(4):733-8. PubMed ID: 14962945 [TBL] [Abstract][Full Text] [Related]
17. Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome. Wang XH; Liu SQ; Wang YL; Jin Y Genet Mol Res; 2014 Jun; 13(2):4260-6. PubMed ID: 25036169 [TBL] [Abstract][Full Text] [Related]
18. The effects of short term (3 weeks) testosterone treatment on serum inflammatory markers in men undergoing coronary artery stenting. Guler N; Batyraliev T; Dulger H; Ozkara C; Tuncer M; Aslan S; Okut H; Agirbasli M Int J Cardiol; 2006 May; 109(3):339-43. PubMed ID: 16040142 [TBL] [Abstract][Full Text] [Related]
19. [Effect of Xinmaitong capsule on serum matrix metalloproteinases-9, high sensitive C-reactive protein levels in patients with acute coronary syndrome]. Meng J; Qin J; Ma Y; Sun HM; Luo CF; Qiu RX Zhongguo Zhong Yao Za Zhi; 2007 May; 32(9):850-2. PubMed ID: 17639992 [TBL] [Abstract][Full Text] [Related]
20. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome. Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM Clin Chim Acta; 2006 Jun; 368(1-2):183-7. PubMed ID: 16472797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]